http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103555744-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7d927148c7982a59521f5c2ed8ae37c0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2013-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48dd48e12803f76f5fa4c7d00e3d5096 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13b5f2fdf3ea16f99fc78b5b930afeb1 |
| publicationDate | 2015-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103555744-B |
| titleOfInvention | Nucleotide sequence and amino acid sequence of arenicola cristata protease gene with antineoplastic activity |
| abstract | The invention relates to a nucleotide sequence for coding an arenicola cristata protease gene and an amino acid sequence of the arenicola cristata protease gene, and belongs to the field of biomedical engineering. The nucleotide sequence is 880bp in full length; the nucleotide sequence for coding arenicola cristata protease is 813bp in length; the whole amino acid sequence of coded arenicola cristata protease is equal to 270 amino acid residues, and signal peptide formed by 15 amino acid residues is contained. The nucleotide sequence for coding the arenicola cristata protease gene and the amino acid sequence of the arenicola cristata protease gene have the beneficial effects that a coding gene of the protease can be cloned from digestive tract tissue of arenicola cristata according to a cDNA (complementary Deoxyribose Nucleic Acid) sequence of arenicola cristata protease; the coding gene can be expressed in a prokaryotic expression system through the gene recombination technology; the recombinant arenicola cristata protease has the activity of inhibiting tumor cell proliferation, and can be used as a potential antineoplastic drug in the gene engineering to be further developed. |
| priorityDate | 2013-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 201.